Spero Therapeutics (SPRO) Net Equity Issued and Repurchased (2016 - 2023)

Spero Therapeutics (SPRO) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $1000.0 in Q4 2023.

• Quarterly Net Equity Issued and Repurchased rose 101.79% year-over-year to $1000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $221000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $221000.0, down 97.85% from the prior year.
• Net Equity Issued and Repurchased slipped to $1000.0 in Q4 2023, from $220000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $40.0 million in Q2 2021 to a low of -$38.9 million in Q3 2021.
• A 5-year average of $4.4 million and a median of $2.8 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased jumped 4878.95% — and 2021, when it slumped 2155.81%.
• Tracing SPRO's Net Equity Issued and Repurchased over 5 years: stood at $5.5 million in 2019, then retreated by 27.23% to $4.0 million in 2020, then plunged by 233.82% to -$5.4 million in 2021, then surged by 98.95% to -$56000.0 in 2022, then surged by 101.79% to $1000.0 in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $1000.0 (Q4 2023), $220000.0 (Q3 2023), and -$56000.0 (Q4 2022), per Business Quant data.